title: Reactogenicity and immunogenicity of measles-rubella combined vaccine in school-entry-aged subjects with naturally acquired measles immunity.
abstract: BACKGROUND
  The reintroduction of measles-rubella combined (MR) vaccination to Japan raised concerns about adverse events as well as immunogenicity related to booster immunization in subjects with naturally acquired immunity to measles or rubella.
  
  
  METHODS
  The time course of reactogenicity and antibody responses in recipients with pre-existing immunity to measles through natural infection was observed. Eighteen children aged 80-104 months received MR booster vaccination; 16 of them had had previous rubella vaccination.
  
  
  RESULTS
  There were virtually no clinical reactions related to booster vaccination, and a highly significant antibody response to rubella antigen, whereas the antibody rise to measles was statistically significant but poor.
  
  
  CONCLUSIONS
  Vaccination of individuals already immune is not harmful. Booster immunization to rubella for Japanese children is vitally important.
authors: Pediatric Allergy and Infectious Diseases Society of Sapporo, Kumagai Pediatric Clinic, Sapporo, Japan.
authors: Takuji
authors: T
authors: Kumagai
authors: Department of Pediatrics, National Hospital Organization Mie National Hospital, Tsu, Japan.
authors: Toshiaki
authors: T
authors: Ihara
authors: Laboratory of Viral Infection I, Kitasato Institute for Life Sciences, Tokyo, Japan.
authors: Tetsuo
authors: T
authors: Nakayama
authors: Pediatric Allergy and Infectious Diseases Society of Sapporo, Hiraoka-Kohen Pediatric Clinic, Sapporo, Japan.
authors: Nobuo
authors: N
authors: Nagata
authors: Laboratory of Viral Infection I, Kitasato Institute for Life Sciences, Tokyo, Japan.
authors: Hitoshi
authors: H
authors: Kamiya
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D002648:Child; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007113:Immunity, Innate; D007074:Immunoglobulin G / Q000276:immunology*; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control*; D022542:Measles-Mumps-Rubella Vaccine / Q000494:pharmacology*; D009107:Mumps / Q000453:epidemiology / Q000517:prevention & control*; D012189:Retrospective Studies; D012409:Rubella / Q000453:epidemiology / Q000517:prevention & control*; D012574:Schools; D014611:Vaccination / Q000379:methods
chemical_list: D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; D022542:Measles-Mumps-Rubella Vaccine
keywords: antibody; measles-rubella combined vaccine; reactogenicity